Max Bittrich
University of Erlangen-Nuremberg
7 Papers
8 Citations
Max Bittrich is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: DNA methylation & Elotuzumab. The author has an hindex of 3, co-authored 7 publications.
Chat about Author
Papers
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy
Sophia Danhof,Susanne Strifler,Dorothea Hose,Martin Kortüm,Max Bittrich,Jochen Hefner,Hermann Einsele,Stefan Knop,Martin Schreder +8 more
TL;DR: In this article, the authors analyzed safety and efficacy of elotuzumab/immunomodulatory drug combinations in a real-life cohort of 33 patients from the same institution.
18
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Dorothea Hose,Martin Schreder,Jochen Hefner,Max Bittrich,Sophia Danhof,Susanne Strifler,Maria-Theresa Krauth,Renate Schoder,Bettina Gisslinger,Hermann Einsele,Heinz Gisslinger,Stefan Knop +11 more
TL;DR: Elo/pom/dex is an active and well-tolerated regimen in highly advanced MM even after pretreatment with pomalidomide and the most frequent grade 3/4 adverse events were neutropenia and pneumonia.
Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma
Larissa Haertle,Santiago Barrio,Michal Simicek,Umair Munawar,Ricardo Sanchez,Max Bittrich,Matteo DaVia,Cornelia Vogt,Nicola Giesen,Andoni Garitano-Trojaola,Silvia Nerreter,Thorsten Stuehmer,Marc S. Raab,Joaquin Martinez Lopez,Roman Hájek,Hermann Einsele,Leo Rasche,Thomas Haaf,Martin Kortüm +18 more
TL;DR: It is confirmed that patients with high methylation had low expression of PSMD5 and vice versa, and epigenetic silencing by promoter hypermethylation (methylation degree ≥15%) in 20% of PI resistant patients is demonstrated, at RNA level.
4
Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease.
Antonio Giovanni Solimando,Matteo Claudio Da Via,Paola Borrelli,Patrizia Leone,Giuseppe Di Lernia,Paula Tabares Gaviria,Andreas Brandl,Giacinto Luca Pedone,Hilka Rauert-Wunderlich,Constantin Lapa,Silvio Tafuri,Francesco Paolo Bianchi,Roberto Ria,Max Bittrich,Domenico Ribatti,Andreas Rosenwald,K. Martin Kortüm,Vito Racanelli,Angelo Vacca,Hermann Einsele,Andreas Beilhack +20 more
TL;DR: It is hypothesized that alterations in the adhesion molecules, particularly JAM-A expression, on MM plasma cells (MM-PCs) may play a pivotal role in high-risk EMD patients, and data provide a biological rationale for a Jam-A guided decision-making process to better combine molecular and immunochemo-therapy modalities in the EMD MM patient subset.
4
Lenalidomide, Adriamycin and Dexamethasone (RAD) Versus Bortezomib, Lenalidomide and Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) - Post-Induction Response and MRD Results By Flow Cytometry and NGS from a Phase 3 Randomized Controlled Clinical Trial (RCT)
Thomas Stübig,Christian Langer,Monika Engelhardt,Lars-Olof Mügge,Florian Bassermann,Martin Schreder,Kerstin Schäfer-Eckart,Igor Wolfgang Blau,Denise Wolleschak,Albrecht Reichle,Ivana von Metzler,Bernd Metzner,Christoph Röllig,Bernd Hertenstein,Heinz Dürk,Harald Biersack,Helge Dr Menzel,Tobias Dechow,Jan Schleicher,Martin Gramatzki,Tim H. Brümmendorf,Stephan Fuhrmann,Max Bittrich,Franziska Appelt,Martina Müller,Jan Krönke,Julia Reusch,Christian Schmidt,Monika Brüggemann,Swantje Held,Stefan Knop,Hermann Einsele +31 more
TL;DR: The study was powered to confirm non-inferiority of RAD at a margin of 10% with a one-sided alpha level of .05 and evaluated the applicability of comprehensive immunoglobulin next generation sequencing (NGS) to detect molecular MRD markers and to compare the results with FC.
1